Intellia Therapeutics (NTLA) Stock
Intellia Therapeutics (NTLA) closed at $9.78 on Nov 17, 2026; its Tenet Score is 41 of 100 against 340 Healthcare peers.
25 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $9.78
- Nov 17, 2026
- Market cap
- $1.4B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 7.95 – 18.48
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 41/100
- Weak · 340 Healthcare peers
Industry: Drugs
Intellia Therapeutics Inc scores 41/100. Weak. Strongest on value and financial health, quality is the soft spot versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
13F flows & insider trades land here.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the tre…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Pacira BioSciences IncPCRX | 56 | $1.5B |
| UroGen Pharma LtdURGN | 44 | $1.4B |
| AlvotechALVO | 41 | $1.4B |
| AnaptysBio IncANAB | 53 | $1.4B |
| Novavax, Inc.NVAX | 37 | $1.3B |
| Taysha Gene Therapies IncTSHA | 58 | $1.3B |
| Ocular Therapeutix IncOCUL | 51 | $1.3B |
| Innoviva IncINVA | 73 | $1.3B |
| Absci CorpABSI | 39 | $1.3B |
| Mineralys Therapeutics IncMLYS | 55 | $1.3B |
Compare Intellia Therapeutics with
Common questions
What sector and industry is Intellia Therapeutics in?
Intellia Therapeutics is in the Healthcare sector and the Drugs industry.
What is Intellia Therapeutics' Tenet Score?
Intellia Therapeutics' Tenet Score is 41 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




